spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share

Gerresheimer AG


Duesseldorf, June 24, 2020—Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG.

“In 2019, we paved the way for profitable growth and achieved a substantial improvement in the Company’s culture and dynamic. We are investing and working to grow our innovation pipeline. These efforts continue undiminished and we have not been distracted by the Covid-19 pandemic. As a key supplier to the pharma and healthcare industry, we have significant responsibility for ensuring patients receive the medication they need and thus in maintaining our customers’ delivery capacity. We have guaranteed this over the past few months and maintained our own delivery capacity at all times. At present, we are seeing new opportunities arise in the pharma business. What is very high demand for injection vials for future Covid-19 vaccination campaigns is currently providing tailwind. Our clear-cut goal is to set our Gerresheimer on the path to sustainable, profitable growth,” said Dietmar Siemssen, CEO of Gerresheimer AG, at the Annual General Meeting.

The dividend has been raised by 4% to EUR 1.20 per dividend-entitled share, compared with a dividend of EUR 1.15 per share distributed in the prior year. The dividend will be paid out on June 29, 2020.A large majority voted in favor of the resolution formally ratifying the actions of the Management Board and Supervisory Board in the financial year 2019. Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Duesseldorf, was elected as auditor for the financial year 2020.

A resolution was also passed to amend the Articles of Association to include provisions on the proof of share ownership to be submitted by a shareholder when registering for the Annual General Meeting. This amendment was made necessary by changes to the German Stock Corporation Act.

At today’s Annual General Meeting, 86.03% of the capital stock was represented. The detailed voting results on all items of the Annual General Meeting agenda are available here:

The speech delivered by the CEO at the Annual General Meeting is available here:

The Annual Report is available here:
phone +49-(0)211/61 81-00
email info@gerresheimer.com
web www.gerresheimer.com
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>


White Papers

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement